SurGenTec received FDA clearance to market TiLink-P, a minimally invasive implant for the treatment of chronic sacroiliac (SI) joint pain.
TiLink-P combines compression across the sacroiliac joint with a posterior implantation approach, offering physicians the ability to stabilize the region. This minimally invasive technology requires one small incision and one integrated implant, in contrast to current methods that require multiple incisions and large bulky implants. TiLink-P additionally allows for the ability to dispense copious amounts of bone graft within and around the implant. This may enhance fusion and potentially provide a greater chance of a successful surgical outcome.
TiLink, a 3D-printed titanium implant, features Nanotex surface technology and a trellis system designed to help promote osteointegration. To streamline the minimally invasive implantation process, SurGentec has developed user-friendly instruments with reduced steps.
SurGenTec now offers an extensive portfolio of SI joint fusion technologies. With the recent FDA clearance of Tilink lateral sacroiliac fusion system, SurGenTec’s family of SI joint fusion products now offers healthcare professionals the ability to select the most appropriate implant and approach given the most challenging pathologies and diverse patient selection.
Travis Greenhalgh, Chief Executive Officer at SurGenTec, said, “By combining the power of compression across the SI joint with the muscle-sparing posterior approach and the ability to reinforce with bone graft, TiLink offers surgeons a new and efficient way to enhance healing in patients.”
SurGenTec received FDA clearance to market TiLink-P, a minimally invasive implant for the treatment of chronic sacroiliac (SI) joint pain.
TiLink-P combines compression across the sacroiliac joint with a posterior implantation approach, offering physicians the ability to stabilize the region. This minimally invasive technology requires one...
SurGenTec received FDA clearance to market TiLink-P, a minimally invasive implant for the treatment of chronic sacroiliac (SI) joint pain.
TiLink-P combines compression across the sacroiliac joint with a posterior implantation approach, offering physicians the ability to stabilize the region. This minimally invasive technology requires one small incision and one integrated implant, in contrast to current methods that require multiple incisions and large bulky implants. TiLink-P additionally allows for the ability to dispense copious amounts of bone graft within and around the implant. This may enhance fusion and potentially provide a greater chance of a successful surgical outcome.
TiLink, a 3D-printed titanium implant, features Nanotex surface technology and a trellis system designed to help promote osteointegration. To streamline the minimally invasive implantation process, SurGentec has developed user-friendly instruments with reduced steps.
SurGenTec now offers an extensive portfolio of SI joint fusion technologies. With the recent FDA clearance of Tilink lateral sacroiliac fusion system, SurGenTec’s family of SI joint fusion products now offers healthcare professionals the ability to select the most appropriate implant and approach given the most challenging pathologies and diverse patient selection.
Travis Greenhalgh, Chief Executive Officer at SurGenTec, said, “By combining the power of compression across the SI joint with the muscle-sparing posterior approach and the ability to reinforce with bone graft, TiLink offers surgeons a new and efficient way to enhance healing in patients.”
Copy to clipboard 
